General MedicationsNASALStandard
SUMATRIPTAN
SUMATRIPTAN
Standard Dose
20MG/SPRAY
Max Dose
Refer to approved labeling
Primary Use
Review priority: UNKNOWN Marketing status: Prescription
Summary
Approval overview SUMATRIPTAN is listed in Drugs@FDA under application 214209 (ANDA).
Review priority: UNKNOWN Marketing status: Prescription Active ingredient SUMATRIPTAN Form and strength SPRAY;NASAL - 20MG/SPRAY Sponsor CIPLA Submission history Latest submission status date: 2024-06-05 00:00:00.
Structured Monograph
Clinical summary
Approval overview SUMATRIPTAN is listed in Drugs@FDA under application 214209 (ANDA). Review priority: UNKNOWN Marketing status: Prescription Active ingredient SUMATRIPTAN Form and strength SPRAY;NASAL - 20MG/SPRAY Sponsor CIPLA Submission history Latest submission status date: 2024-06-05 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: UNKNOWN
Interaction Notes
- No interaction notes stored yet.